Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inaticabtagene Autoleucel for B-ALL in First Complete Remission
NCT06777264Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
01
Overview
A Phase 2 trial of inaticabtagene autoleucel in B cell acute lymphoblastic leukemia (B-ALL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
inaticabtagene autoleucel
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06777264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06777264.